Outcome of Board Meeting under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Kimia Biosciences' Board met on August 14, 2025 and approved the unaudited standalone financial results for Q1 FY26 (quarter ended June 30, 2025). Revenue from operations rose modestly to about Rs. 23.58 crore from Rs. 22.40 crore in Q1 FY25, a growth of around 5%. However, profit after tax fell sharply to Rs. 60.40 lakh from Rs. 143.70 lakh a year ago, a decline of nearly 58%, as total expenses grew much faster than revenue. The Board also noted a warning letter from BSE dated July 25, 2025 over delays in filing the Annual Report for FY24, approved raising an unsecured loan of Rs. 2 crore at 8% per annum interest, and appointed Mr. Pradip Kumar Sharma as the new CFO with immediate effect.
Sharp drop in profitability despite steady revenue signals margin pressure and rising costs, which is negative for shareholders. The BSE warning letter adds a minor governance red flag, while the small unsecured loan and new CFO appointment are routine operational matters.